Company intelligence / Profile preview

Ocean Trans Biotechnology

Haikou, Hainan, China

Ownership: Private
Employees: ~150
Development stage: Other

Overview

Ocean Trans is a specialty pharmaceutical company focused on high-end controlled-release oral dosage forms using its proprietary osmotic pump (OROS) technology. Its lead program, YY-103 (Paliperidone Extended-release Tablets), has received marketing approval in China, and several other programs including YY-101 (Nifedipine) and YY-102 (Doxazosin) are in late-stage clinical development or regulatory filing stages in both China and the US.

Therapeutic areas: PsychiatryCardiovascularMen's HealthNeurology
Modalities: Small moleculeDrug delivery platform
Industry: Biotech

Partnerships

Simcere Pharmaceutical Group

Beyond the preview

Go deeper on Ocean Trans Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ocean Trans Biotechnology.

Explore the full profile